MRTX News and Press, Mirati Therapeutics Inc. From 02/28/23

Mirati Therapeutics press release ( NASDAQ: MRTX ): Q4 GAAP EPS of -$3.51 beats by $0.16 . Revenue of $0.93M (+210.0% Y/Y) misses by $1.72M . For further details see: Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M

Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announ...

Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference PR Newswire SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the 43 rd Annual Cowen Heal...

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023 PR Newswire SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company...

Summary Today, we take a deeper look at mid-cap oncology name Mirati Therapeutics for the first time in several years. The company's first FDA approval and some other positive milestones have been overshadowed over the past two months by some disappointing trial data. This has cause...

Mirati Therapeutics ( NASDAQ: MRTX ) on Thursday said the U.S. Food and Drug Administration had cleared its investigational new drug (IND) application for its inhibitor MRTX1133. MRTX1133 is an investigational inhibitor that targets a type of mutation in multiple cancer types called K...

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133 PR Newswire IND demonstrates Mirati's leadership in KRAS, representing the Company's third KRAS or KRAS-signaling program to enter clinical dev...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Nixx Photography Chinese electric vehicle (EV) stocks are a chief concern among investors today as these shares see mixed trading. Investors continue to watch Chinese stocks like a hawk for sign...